Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment. * Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator. * Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements. * Willingness to avoid pregnancy or fathering children as defined in the protocol. * Willingness and ability to comply with the study Protocol and procedures. Exclusion Criteria: * Had been permanently discontinued from study treatment during the parent study. * Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study. * Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study: * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab). * Live, attenuated vaccine. * Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class. * Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. * Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. Other protocol-defined Inclusion/Exclusion Criteria may apply.